Pharmaceutical Business Review
Anonymous User | Login

Latest Pharmaceutical News

Glenmark Generics, Konec Receive Order From FDA To Stop Marketing Unapproved Nitroglycerin Tablets

FDA has ordered Glenmark Generics and Konec of Tucson, Ariz, to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3mg, 0.4mg, and 0.6mg dosages.

Published: 17-Mar-2010

Savient Pharma Refiles Biologics License Application For Krystexxa

Savient Pharma has resubmitted its biologics license application (BLA) to FDA for Krystexxa (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.

Published: 16-Mar-2010

Eli Lilly, Amylin Pharma, Alkermes Receive Complete Response Letter For Bydureon

Eli Lilly, Amylin Pharma and Alkermes have received complete response letter from FDA regarding the new drug application (NDA) for Bydureon (exenatide for extended-release injectable suspension).

Published: 15-Mar-2010

GSK Receives Marketing Authorisation For Revolade

GlaxoSmithKline (GSK) has received marketing authorisation from European Commission (EC) for its Revolade (eltrombopag), used in the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Published: 15-Mar-2010

MorphoSys Gets Japanese Patent For Core Antibody Technology HuCAL

MorphoSys has received a new patent from Japanese Patent Office for its core antibody technology HuCAL, which is processed and transmitted by Hugin.

Published: 15-Mar-2010

Ranbaxy, Takeda Pharma Settle Actos Patent Litigation

Ranbaxy Laboratories, with its wholly owned subsidiary Ranbaxy Pharmaceuticals (RPI), has reached an agreement with Takeda Pharma Company and Takeda Pharmaceuticals North America, to settle pending patent litigation regarding generic equivalent version of Actos (Pioglitazone Hydrochloride) 15mg, 30 mg and 45 mg tablets of Ranbaxy.

Published: 15-Mar-2010

Sanofi-aventis, Bristol-Myers Squibb Update On Plavix US Prescribing Information

Sanofi-aventis US and Bristol-Myers Squibb have come out with revisions to the US prescribing information for Plavix (clopidogrel bisulfate), which include a boxed warning, which concerns the diminished effectiveness of Plavix in patients who have a genetic variation causing reduced formation of the active metabolite.

Published: 12-Mar-2010

Abbott Seeks FDA Approval For Lupron Depot 45-mg Six Month Formulation

Abott has reported that the FDA has accepted review of the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.

Published: 12-Mar-2010

FDA Gives Nod To Five-Day Dosing Regimen Of Dacogen To Treat MDS Patients

Eisai, a US-based pharma company, has received approval from US FDA for a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

Published: 11-Mar-2010

NeoPharm Files ODA For IL13-PE38QQR

NeoPharm has filed an orphan drug application (ODA) with the Office of Orphan Products Development of the FDA to have orphan drug designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Published: 11-Mar-2010

Browse Archived News

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address